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In common with other E2F1 responsive genes such as p14
ARF and B-myb, the promoter of p73 is shown to be positively
regulated in cell lines and primary human keratinocytes by E7 proteins from oncogenic human papillomavirus (HPV) types 16,
18, 31 and 33, but not HPV 6. Mutational analysis revealed that transactivation of the p73 promoter by HPV 16E7 requires
association with pRb. Expression of p73 in normal cervical epithelium is conﬁned to the basal and supra-basal layers. In
contrast, expression in neoplastic lesions is detected throughout the epithelium and increases with grade of neoplasia, being
maximal in squamous cell cancers (SCC). Deregulation of expression of the N-terminal splice variant p73D2 was observed in
a signiﬁcant proportion of cancers, but not in normal epithelium. The frequent over-expression of p73D2, which has
recognized transdominant properties, in malignant and pre-malignant lesions suggests a role in the oncogenic process in
cervical epithelium.
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p73 has structural and functional homologies to p53, including
sequence-speciﬁc DNA binding and transactivation (Kaghad et
al, 1997). Over-expression of p73 is able to induce apoptosis
in some human cancer lines (Jost et al, 1997) and expression
of p73 has been shown to have a role in the differentiation of
keratinocytes (De Laurenzi et al, 2000). p73 exists in a number
of isoforms which arise by alternative splicing of exons encoding
the 7COOH terminus of the protein and which exhibit differ-
ences in trans-activating and growth suppressor functions (De
Laurenzi et al, 1998). Expression of a transdominant variant
lacking exon 2 (p73 D2) has been described in ovarian cancer
(Ng et al, 2000) and in breast cancer cell lines (Fillippovich et
al, 2001). Recently, p73 has been shown to be directly induced
by E2F1 and thereby to contribute to E2F1-mediated apoptosis
(Irwin et al, 2000; Lissy et al, 2000). Furthermore, both myc
and adenovirus E1A can activate expression of p73 (Zaika et
al, 2001).
Although p73 is subject to methylation-dependent transcrip-
tional silencing in some B-cell malignancies, consistent with a
role as a putative tumour suppressor protein (Corn et al, 1999),
mutational analyses have suggested that it is rarely mutated in
human cancers. Furthermore, p73 is over-expressed in some
cancers, although the mechanism of this is unknown (Chi et al,
1999; Zaika et al, 1999).
Squamous cell carcinoma of the cervix is the second most
common female cancer. The majority of cervical SCC contain
and express sequences from oncogenic HPV types, principally
HPV 16, 18 and 31. Two proteins, E6 and E7, encoded by
oncogenic HPV types have critical roles in carcinogenesis.
E7 is able to associate with and functionally inactivate the
protein (pRb) encoded by the RB gene. Expression of both
E6 and E7 is necessary for immortalization of primary genital
keratinocytes (Hawley-Nelson et al, 1989), implying that
continued expression of HPV-encoded oncoproteins will be
fundamental to growth of HPV positive cancer cells.
The association of E7 with pRb causes release of E2F1
from complexes with pRb resulting in expression of a number
of genes with critical functions in the control of cellular
proliferation including p14
ARF, the alternative product of the
INK4 locus (Bates et al, 1998) and B-myb (Lam et al,
1994). Expression of p14
ARF is hypothesized to protect cells
from oncogenic events by inhibiting MDM2-dependent degra-
dation of p53, facilitating p53-induced apoptosis and cell
cycle arrest (Bates et al, 1998). Induction of p14
ARF expres-
sion by E2F1 is consistent with such a function, since
expression of other oncoproteins, such as adenovirus E1A
and SV40 T, also results in deregulation of E2F1 (Zaika et
al, 2001). In this study, we have investigated the deregulation
of p73 by HPV E7, both in vitro and in clinical biopsies
positive for HPV 16.
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Transient assays
H1299 cells were maintained in DMEM with 10% foetal bovine
serum. Primary human keratinocytes were purchased from
Clonetics and grown according to the manufacturer’s instructions.
H1299 cells were transfected by the calcium phosphate method and
primary keratinocytes using Effectene (Qiagen) following the
manufacturer’s instructions. Transfection efﬁciency was controlled
by inclusion of pSV b-gal in each assay. Luciferase activity was
determined using the Promega assay system and normalized to
b-galactosidase activity. The reporter plasmids were p73 luciferase
(Ding et al, 1999), p14
ARF luciferase (Bates et al, 1998) and B-
myb luciferase (Lam et al, 1994). Each transfection included 1 mg
of reporter. HPV 16E7 expression plasmids were constructed by
sub-cloning into pcDNA3 inserts from pMo16E7, pMo24Gly,
pMo26Gly and pMoD21-35 (Edmonds and Vousden, 1989). Plas-
mids for expression of E7 from other HPV types were
constructed by sub-cloning the inserts from pJ4D E7 plasmids
previously described into pcDNA3 (Storey et al, 1989). The adeno-
virus expression plasmid was pE1A (Zaika et al, 2001).
Cervical tissue specimens
Cervical carcinomas, cervical intraepithelial neoplasia (CIN) tissues
and matched, normal cervical epithelium were obtained at hyster-
ectomy or cone biopsy. In each case the diagnosis was checked by
histopathological analysis, and a majority of neoplastic cells in the
tissue for analysis was conﬁrmed. Tissues were collected immedi-
ately into liquid nitrogen and stored until analysis. Genomic
DNA was isolated by proteinase-K digestion and total RNA by
RNAzol B. HPV DNA sequences were sought by in all specimens
using type speciﬁc PCR for HPV types 16, 18, 31, 33 and 39 as
described by Walboomers et al. (1999). Parafﬁn sections of cervical
neoplasia for immunocytochemistry were retrieved from the
Department of Histopathology at St Mary’s Hospital, London.
Analysis of gene expression of p14
ARF and p73
cDNA was synthesised with the ProStar system (Stratagene) from
3 mg of total RNA. Analysis of expression was performed by
RT–PCR as described previously for p14
ARF (Gazzeri et al,
1998), and p73 (De Laurenzi et al, 1998). For semi-quantitative
analysis of gene expression, PCR was performed using the primers
and thermal cycling conditions described and was for 22 cycles for
p14
ARF, and 28 cycles for p73. In some experiments, ampliﬁcation
was extended to 40 cycles to analyze expression in tissues expres-
sing a lower level of p73. Following PCR, reactions were resolved
on agarose gels, transferred to Hybond-N
+ nylon and hybridized
with
32P g-ATP-labelled oligonucleotide probes speciﬁc for the
ampliﬁed fragments. Analysis of N-terminal splice variants of p73
was performed using the primers described (Ng et al, 2000). Iden-
tity of these was conﬁrmed by cloning and sequencing and by
hybridization analysis of ampliﬁed products with oligonucleotide
probes speciﬁc for exon 2 and exon 3 of p73. The presence of
equivalent amounts of cDNA in each PCR was veriﬁed by ampliﬁ-
cation of b-actin under similar limiting conditions.
Immunocytochemistry
Sections (5 mm) were cut from formalin-ﬁxed, parafﬁn-embedded,
tissue sections. The diagnosis in each case was conﬁrmed by exam-
ination of haematoxylin and eosin-stained sections. For
immunocytochemistry, sections were pressure-cooked in citrate
buffer, then stained with antibodies: p14
ARF goat polyclonal
(C20, Santa Cruz, SC-8613) was used at 1/100 dilution; p73 mouse
monoclonal antibody (Neomarkers, MS-764-P0) afﬁnity-puriﬁed
and diluted 1/150. Sections were scored independently by at least
two pathologists.
RESULTS
p73 is deregulated by HPV 16E7
Analysis of the effect of expression of HPV 16E7 on the activity of
the p73 promoter was performed in transient assays in human
H1299 cells in which the RB gene is intact. Consistent with previous
studies, E2F1 strongly activates the p73 promoter (Figure 1A).
Expression of HPV 16E7 results in a dose-dependent increase in
activity from the p73 promoter (Figure 1A). The increase in activity
from the p73 promoter was comparable to that observed from the
promoters of two other recognized E2F1-responsive genes, p14
ARF
and B-myb, in parallel transfections (Figure 1B). We were next inter-
ested to determine whether deregulation of p73 was restricted to
oncogenic HPV types associated with cervical cancer and high-grade
pre-neoplastic lesions. We therefore analyzed the ability of E7
proteins of ‘high-risk’ HPV types (16, 18, 31 and 33) and the
‘low-risk’ HPV 6 to activate expression from the p73 promoter.
These studies revealed that activation of p73 occurred with signiﬁ-
cantly greater efﬁciency in the case of the oncogenic HPV types,
whereas this activity was virtually undetectable in HPV 6 E7 (Figure
1C). As previously reported (Zaika et al, 2001), adenovirus E1A also
activated the p73 promoter (Figure 1C). One of the differences
between the high and low risk E7 proteins is the ability to complex
with pRb (Munger et al, 1989). We investigated the potential role of
this interaction by analysis of a series of mutants of HPV 16E7
(Edmonds and Vousden, 1989). As observed previously, expression
of wild-type HPV16 E7 reproducibly results in increased activity
from the p73 promoter, but mutants E7D21-35 and E7 Gly 24,
which do not associate with pRb, failed to increase activity from
the p73 promoter (Figure 1D). E7 Gly 26, which fails to associate
with pRb yet retains binding to p107, also fails to transactivate
p73. These results are consistent with deregulation of p73 expression
by HPV 16E7 via E2F1 through association with pRb. Consistent
with this hypothesis, expression of HPV 16E7 in the Saos-2 cell line,
which lacks endogenous pRb, failed to transactivate the p73 promo-
ter (data not shown).
HPV E7 activates expression of p73 in human keratinocytes
To verify the results obtained in transient assays in H1299 cells, we
performed similar analysis in primary cultures of human keratino-
cytes. In agreement with the data from H1299, HPV 16E7 activated
expression from the p73 promoter, albeit at lower levels than
observed in H1299, whereas HPV 6E7, 16E7 Gly24 and 16E7 21-
35D lacked this activity (Figure 2A). Having observed activation
of p73 by oncogenic HPV types in transient assays, we next deter-
mined whether steady-state levels of p73 RNA are elevated in
keratinocyte cell lines expressing HPV 16E7. In primary keratino-
cytes, a number of isoforms of full-length p73 were identiﬁed by
RT–PCR, consistent with previous studies (De Laurenzi et al,
1998), although the principal variants were p73a and p73g (Figure
2B). In two keratinocyte cell lines which stably express HPV 16E7,
there is clearly elevated expression of both full-length p73a, p73b
and p73g relative to primary keratinocytes (Figure 2B).
p73 is deregulated as full-length and D2 variants in
anogenital neoplasia
To address the relevance of the results obtained from transient
assays and cell lines, we performed RT–PCR and immunocyto-
chemical analysis of p73 expression in primary cervical tissues,
these comprising a series of HPV 16 positive CIN I, CIN III and
cervical SCC (Figures 3 and 4). Using cycling conditions from
the exponential portion of the PCR ampliﬁcation curve, expression
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British Journal of Cancer (2002) 86(2), 263–268 ã 2002 The Cancer Research Campaign(predominantly of the full-length a form) was detectable in 11 out
of 78 samples of normal cervical epithelium. Analysis of cervical
intra-epithelial neoplasia (CIN) I samples also failed to detect
p73 mRNA in the majority of cases under similar conditions. In
contrast, although expression in cervical SCC is also restricted to
the a form in almost all cases, steady-state levels of p73 mRNA
are markedly increased relative to matched normal tissue in 64
out of 78 (82%) of the cases analyzed (Figure 3A). Elevated expres-
sion was observed in nine out of 14 (64%) cases of CIN III, in each
case only the a variant being detected. To determine whether
samples apparently negative for p73 under these limiting condi-
tions actually expressed low levels of mRNA, PCR was repeated
using 40 rather than 28 cycles. Under such conditions, p73 RNA
was detected in 72 out of 78 of the normal samples analyzed
and eight out of eight of the CIN I samples. This result is consis-
tent with immunocytochemical detection of p73 protein (see
below).
The over-expression of p73a in a high proportion of cases of
cervical neoplasia was somewhat unexpected in view of the recog-
nized apoptotic and negative growth regulatory functions of p73.
We therefore performed additional RT–PCR analyses to examine
the N-terminus of the p73 mRNA species expressed in cervical
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Figure 1 The p73 promoter is activated by HPV E7 proteins in H1299 cells. (A) Cells were transfected with p73 luciferase, and the indicated amounts of
either pcDNA E2F1 or pcDNA3 16E7. Luciferase activity was determined after 48 h as described in Materials and Methods. Data shown are means of
luciferase activity relative to cells receiving only empty vector +s.d. of at least eight experiments. (B) Activation of the p73, p14
ARF and B-myb promoters
by HPV 16E7. H1299 cells were transfected with the indicated luciferase reporter plasmids, and the indicated, increasing amounts of pcDNA3 16E7.
Luciferase activity was determined after 48 h as described in Materials and Methods. Data shown are means of relative luciferase activity +s.d. of at least
six experiments. (C) Activation of the p73 promoter by E7 proteins from ‘oncogenic’ HPV types. Cells were transfected with p73 luciferase and pcDNA E7
plasmids from the indicated HPV types or empty vector alone (V). Luciferase activity was determined after 48 h as described in Materials and Methods. Data
shown are means of relative luciferase activity +s.d. of at least six experiments. (D) Activation of p73 is abrogated by mutants lacking binding to pRb. Cells
were transfected with p73 luciferease and the indicated HPV E7 expression plasmids or empty vector only (V). Luciferase activity was determined after4 8h
as described in Materials and Methods. Data shown are means +s.d. of at least six experiments
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 263–268tissues. In these experiments we detected over-expression of the D2
variant in the majority of cervical SCC shown in previous analyses
to over-express p73a (Figure 3B). There was simultaneous over-
expression of full-length p73 in approximately 50% of the cervical
SCC. Immunocytochemical analysis conﬁrmed that the increased
levels of p73 mRNA revealed by RT–PCR in neoplastic epithelium
were reﬂected in protein expression (Figure 4). Expression of p73
was detected in each of the normal epithelial samples analyzed,
consistent with RT–PCR analyses performed under extended
cycling conditions, but was restricted to the basal and suprabasal
layers in all cases analyzed. Expression increased with increasing
grade in CIN. In contrast to normal epithelium, expression was
not restricted to the basal and suprabasal layers but was detectable
throughout the neoplastic epithelium (Figure 4).
p73 expression is deregulated with p14
ARF in
anogenital neoplasia
Finally, we determined the expression levels of another recognised
E2F1 regulated gene, p14
ARF (Bates et al, 1998) in the same samples
analysed for p73. In 62 out of 74 cervical cancers (84%) and 11 out
of 14 CIN III (79%), steady-state levels of p14
ARF mRNA were
clearly elevated relative to matched normal tissue (Figure 3A).
There was simultaneous deregulation of both p73a and p14
ARF in
the majority of cases. Immunocytochemical analysis revealed that,
in agreement with RT–PCR analyses, p14
ARF expression was low
to undetectable in normal cervical epithelium (Figure 4), but was
abundantly expressed in almost all cases of both cervical SCC
and CIN III examined and was over-expressed with p73 in the
great majority of cases. The frequent simultaneous over-expression
of p14
ARF with p73 is consistent with E2F1-driven expression of
both genes.
DISCUSSION
In this work we present data suggesting that functional inactivation
of pRb via interaction with HPV 16E7 results in p73 over-expres-
sion in transient assays and in cell lines expressing E7 from
oncogenic HPV types. We extend these in vitro observations by
demonstrating, at mRNA and protein levels, deregulated expression
of p73 in a high proportion of cervical cancers and pre-malignant
lesions.
Initial studies in H1299 cells conﬁrmed the work of other
authors showing E2F1 transactivation of the human p73 promoter
(Irwin et al, 2000; Lissy et al, 2000), consistent with the presence of
E2F1 consensus binding sites in the p73 promoter (Ding et al,
1999). In conjunction with the subsequent observation that E7-
dependent activation of the p73 promoter is lost in E7 mutants
unable to associate with pRb, these results imply that E7-dependent
transactivation of p73 occurs through E2F1. The strong association
between deregulated expression of p14
ARF and p73 in the CIN III
and SCC is clearly consistent with E2F1-dependent activation of
expression. Taken together, these results all favour the hypothesis
that expression of E7 from oncogenic HPV types results in E2F1-
dependent activation of p73 expression. The ability of E7 proteins
from oncogenic HPV types to activate p73 is further evidence of
functional homologies with E1A and myc, since these oncoproteins
also deregulate p73 expression (Zaika et al, 2001).
p73 is over-expressed in a number of cancers, for example, in
40% of bladder carcinomas (Chi et al, 1999), and in breast adeno-
carcinomas (Zaika et al, 1999), although the mechanism underlying
over-expression has not been elucidated. In these and other studies,
a number of isoforms of p73 generated by alternative splicing of
exons encoding the 7COOH terminus of the protein were
described (De Laurenzi et al, 1998). Keratinocytes derived from
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Figure 2 Expression of p73 is activated by HPV 16E7 in human kerati-
nocytes. (A) Primary human keratinocytes were transfected with p73 luci-
ferease and the indicated pcDNA HPV E7 expression plasmids. Luciferase
activity was determined after 48 h as described in Materials and Methods.
Data shown are means+s.d. of at least three experiments. (B) Steady-
state levels of p14
ARF and 73 mRNA in keratinocyte cell lines expressing
HPV 16 E7. Lanes are: 1
0=primary keratinocytes, HK1 and HK2=keratino-
cyte cell lines immortalized by HPV16 E6 and E7. RT–PCR and hybridiza-
tion was performed as described in Materials and Methods.
p73
p14ARF
actin
full length p73
full length p73
p73D2
actin
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Figure 3 Expression of p14
ARFand p73 in cervical epithelium. RT–PCR
was performed as described in Materials and Methods. (A) p73 is over-ex-
pressed in HPV 16 positive cervical SCC. A single variant of p73 (p73a)i s
predominantly expressed in both normal (N) and malignant (T) cervical
epithelium. The presence of equivalent amounts of cDNA in each sample
was veriﬁed by ampliﬁcation of b-actin as shown. (B) Cervical SCC
express both full-length and D2 forms of p73. RT–PCR for p73D2 was
performed as described in Materials and Methods. Ampliﬁcation products
were resolved on 2% agarose gels, then hybridized with oligonucleotide
probes derived from exon 2 (upper blot) or exon 3 (lower blot). Hybridi-
zation with the probe from exon 2 detects only the full-length transcript,
whereas the probe derived from exon 3 detects both the full-length and
D2 forms of p73. In all cases N=normal tissue, T=tumour. Lanes N6 to
T9 are four matched cases of normal and tumour. Lanes 10–13 are four
examples of cervical SCC, shown without matched normal tissue. The pre-
sence of equivalent amounts of cDNA in each reaction was conﬁrmed by
ampliﬁcation of b-actin as shown in the lower panel.
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British Journal of Cancer (2002) 86(2), 263–268 ã 2002 The Cancer Research Campaignnormal skin also express numerous variants (De Laurenzi et al,
1998), in agreement with the present work. It is of interest, there-
fore, that p73 expression is predominantly of the a isoform in
almost all cases of both normal and neoplastic cervical epithelium
we have studied. Immunocytochemical analysis revealed that
expression of p73 is restricted to the basal and supra-basal layers
in normal cervical epithelium, but becomes far more widespread
in both CIN and in SCC. In many cases, expression occurs
throughout the cancer. We have also observed a striking increase
in expression of p73 with increasing grade of neoplasia.
p73 contributes to the apoptotic function of E2F1 (Irwin et al,
2000; Lissy et al, 2000). In view of this observation and the
hypothesized role of p73 as a tumour suppressor protein, it was
surprising to observe over-expression in such a high-proportion
of cases and to demonstrate a relationship between increasing
grade of neoplasia and expression of p73. Sequencing revealed that
mutations in p73 are extremely rare in cervical cancers (data not
shown), consistent with other authors’ studies of both solid and
haematological malignancies. p73 D2, which lacks exon 2 of p73,
was recently described in ovarian carcinomas (Ng et al, 2000)
and breast cancer cell lines (Fillippovich et al, 2001). p73D2 is able
to inhibit the transactivating functions of both p53 and p73 and, as
such, over-expression of this protein represents a potential
mechanism by which the tumour suppressor properties of these
proteins might be negated or inhibited (Fillippovich et al, 2001).
These authors suggested that analysis of expression of p73D2i na
range of normal and malignant tissues would have considerable
interest. We now demonstrate that this variant is frequently
over-expressed in cervical SCC and this may, at least in part, be
the basis by which the functions of full-length p73a are nulliﬁed
in such cases. Moreover, there is expression of wild-type p53
protein in a high proportion of cervical SCC (Troncone et al,
1998). The ability to inhibit the function of p53 as well as full-
length p73 (Fillippovich et al, 2001) implies that expression of
p73D2 may co-operate with HPV E6 to neutralize p53 in cervical
neoplasia. Furthermore, because full-length p73a functions in path-
ways of keratinocyte differentiation, expression of p73D2 may also
have inhibitory effects on squamous differentiation. Analysis of
p73D2 expression in squamous cancers of varying differentiation
status would clearly be of interest. The high frequency of over-
expression of p73 and p14
ARF in both cervical SCC and CIN, taken
together with the observation of increasing expression with higher
grades of neoplasia, raises the possibility that immunocytochemical
analysis of these proteins may have utility in diagnostic and/or
prognosis in cervical neoplasia. Antibodies speciﬁcally detecting
p73D2 are not yet available. Discrimination between full-length
and p73D2 would further allow deﬁnition of the role of over-
expression of these proteins in squamous neoplasia and their
potential use as markers of cervical neoplasia.
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p14
ARF protein expression is not detectable in normal cervical epithelium.
(D) Over-expression of p14
ARF in cervical SCC. Note the prominent nu-
cleolar expression and sparing of normal tissue.
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